马沃昔福：治疗WHIM综合征的新希望。 - Suppr

Suppr

超能文献

Mavorixafor: a new hope for WHIM syndrome.

作者信息

Geier Christoph B

机构信息

Carl von Ossietzky University Oldenburg and Medical Center University of Freiburg.

出版信息

Blood. 2024 Jul 4;144(1):1-2. doi: 10.1182/blood.2024024942.

DOI:10.1182/blood.2024024942

PMID:38963672

Abstract

摘要

相似文献

Mavorixafor: a new hope for WHIM syndrome.

Blood. 2024 Jul 4;144(1):1-2. doi: 10.1182/blood.2024024942.

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.

Blood. 2024 Jul 4;144(1):35-45. doi: 10.1182/blood.2023022658.

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.

Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197.

A WHIM satisfactorily addressed.

Blood. 2014 Apr 10;123(15):2286-8. doi: 10.1182/blood-2014-02-557579.

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.

J Clin Invest. 2023 Oct 2;133(19):e164918. doi: 10.1172/JCI164918.

Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf014.

Released on a WHIM.

Blood. 2011 Nov 3;118(18):4764-5. doi: 10.1182/blood-2011-08-375162.

Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

J Pediatr. 2012 Oct;161(4):763-5. doi: 10.1016/j.jpeds.2012.05.058. Epub 2012 Jun 27.

Plerixafor for the Treatment of WHIM Syndrome.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646.

引用本文的文献

Targeting the chemokine receptor CXCR4 for cancer therapies.

Biomark Res. 2025 May 1;13(1):68. doi: 10.1186/s40364-025-00778-y.

Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf014.

Neutrophil diversity and function in health and disease.

Signal Transduct Target Ther. 2024 Dec 6;9(1):343. doi: 10.1038/s41392-024-02049-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Mavorixafor: a new hope for WHIM syndrome.

Blood. 2024 Jul 4;144(1):1-2. doi: 10.1182/blood.2024024942.

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.

Blood. 2024 Jul 4;144(1):35-45. doi: 10.1182/blood.2023022658.

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.

Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197.

A WHIM satisfactorily addressed.

Blood. 2014 Apr 10;123(15):2286-8. doi: 10.1182/blood-2014-02-557579.

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.

J Clin Invest. 2023 Oct 2;133(19):e164918. doi: 10.1172/JCI164918.

Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf014.

Released on a WHIM.

Blood. 2011 Nov 3;118(18):4764-5. doi: 10.1182/blood-2011-08-375162.

Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

J Pediatr. 2012 Oct;161(4):763-5. doi: 10.1016/j.jpeds.2012.05.058. Epub 2012 Jun 27.

Plerixafor for the Treatment of WHIM Syndrome.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

N Engl J Med. 2019 Apr 18;380(16):e25. doi: 10.1056/NEJMc1901646.

引用本文的文献

Targeting the chemokine receptor CXCR4 for cancer therapies.

Biomark Res. 2025 May 1;13(1):68. doi: 10.1186/s40364-025-00778-y.

Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf014.

Neutrophil diversity and function in health and disease.

Signal Transduct Target Ther. 2024 Dec 6;9(1):343. doi: 10.1038/s41392-024-02049-y.